Eton Pharmaceuticals (ETON) Liabilities and Shareholders Equity (2017 - 2026)

Eton Pharmaceuticals has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $92.1 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 21.01% year-over-year to $92.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $382.3 million (up 119.0% YoY) and the FY2025 annual result came in at $92.1 million, up 21.01% from the prior year.
• Liabilities and Shareholders Equity retreated to $92.1 million in Q4 2025 per ETON's latest filing, from $104.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $104.5 million in Q3 2025 and troughed at $21.5 million in Q3 2022.
• A 5-year average of $44.1 million and a median of $31.1 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity decreased 25.62% in 2022, then soared 219.5% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $27.5 million in 2021, then fell by 8.87% to $25.0 million in 2022, then gained by 26.81% to $31.7 million in 2023, then jumped by 139.83% to $76.1 million in 2024, then gained by 21.01% to $92.1 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $92.1 million, $104.5 million, and $101.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.